EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide

Ken Okamura

Endocrinology and Metabolism · 31.12.2024 · 39 (6) · 827-838

DOI: 10.3803/enm.2024.2079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.12.2024. Verfasst von Ken Okamura. Beteiligte Einrichtung: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents, Potassium Iodide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graves’ hyperthyroidism is characterized by stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibodies (TRAbs). Antithyroid drug (ATD) continuation is recommended as long as the thyroid gland is stimulated. Goiter size, thyroidal 123I uptake, serum thyroglobulin level, and TRAb positivity are reliable markers of thyroid stimulation. Attention must also be paid to the responsiveness of the thyroid gland due to the high prevalence of painless thyroiditis and spontaneous hypothyroidism during treatment. TRAbs disappeared at 5 years in 21.1% (smoldering-type). Seven percent of patients remained positive for TRAbs for >30 years, requiring life-long ATD treatment. Remission occurred after median 6.8 years (interquartile range, 4.0 to 10.9) of ATD treatment in 55% of patients. However, late relapse may occur after stressful events (dormant type). In apparently intractable Graves’ disease (GD) with a large goiter (>40 g), 131I therapy should be considered. For initial and long-term ATD treatment, we must choose effective, safe, and economical drugs such as 100 mg potassium iodide (KI), although KI sensitivity varies in patients with GD. Thionamide, which has notorious side effects, is added only during the KI-resistant period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseAntithyroid AgentsPotassium IodideHumansFemaleAdultMaleMiddle AgedImmunoglobulins, Thyroid-StimulatingRecurrenceIodine Radioisotopes

Stichwörter der Autor:innen

Antithyroid agentsGraves diseaseHyperthyroidismIodidesThyrotropin-binding inhibitory immunoglobulin

Substanzen

Antithyroid AgentsPotassium IodideImmunoglobulins, Thyroid-StimulatingIodine Radioisotopes

Autor:innen und Institutionen

  • Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Zitieren

APA

Okamura, K. (2024). Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide. Endocrinology and Metabolism, 39(6), 827-838. https://doi.org/10.3803/enm.2024.2079

Vancouver

Okamura K. Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide. Endocrinology and Metabolism. 2024;39(6):827-838. doi:10.3803/enm.2024.2079

BibTeX
@article{Okamura2024,
  author = {Okamura, Ken},
  title = {Long-Term Antithyroid Drug Therapy in Smoldering or Fluctuating-Type Graves’ Hyperthyroidism with Potassium Iodide},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  volume = {39},
  number = {6},
  pages = {827--838},
  doi = {10.3803/enm.2024.2079}
}
Kostenlos starten →